|
Volumn 37, Issue 9, 2005, Pages 3823-3824
|
Influence of the current management of renal transplant recipients on the prevalence of anemia and related costs
|
Author keywords
[No Author keywords available]
|
Indexed keywords
MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;
RECOMBINANT ERYTHROPOIETIN;
ADULT;
AGED;
ANEMIA;
CADAVER DONOR;
CLINICAL TRIAL;
CONFERENCE PAPER;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
COST BENEFIT ANALYSIS;
DISEASE SEVERITY;
FEMALE;
HUMAN;
KIDNEY TRANSPLANTATION;
MAJOR CLINICAL STUDY;
MALE;
MEAN ARTERIAL PRESSURE;
PRIORITY JOURNAL;
PROGNOSIS;
QUALITY OF LIFE;
TREATMENT OUTCOME;
ADULT;
AGE FACTORS;
ANEMIA;
BLOOD PRESSURE;
BODY WEIGHT;
CADAVER;
COST OF ILLNESS;
CREATININE;
FEMALE;
HUMANS;
KIDNEY TRANSPLANTATION;
MALE;
MIDDLE AGED;
POSTOPERATIVE COMPLICATIONS;
RETROSPECTIVE STUDIES;
RISK FACTORS;
SPAIN;
TISSUE DONORS;
|
EID: 29544436132
PISSN: 00411345
EISSN: None
Source Type: Journal
DOI: 10.1016/j.transproceed.2005.09.195 Document Type: Conference Paper |
Times cited : (4)
|
References (5)
|